Constellation Brands Inc. Common Stock vs BIO-TECHNE Corp — how do they compare? Constellation Brands Inc. Common Stock trades at $127.6 (market cap $21.50B), while BIO-TECHNE Corp trades at $72.69 (market cap $11.37B). The key difference: Constellation Brands Inc. Common Stock is the larger of the two by market cap, and Constellation Brands Inc. Common Stock pays the higher dividend (3.24%). Which is the better fit depends on your goals.
| STZ | TECH | |
|---|---|---|
Market Cap | $21.50B | $11.37B |
Volume | 2,104,680 | 2,420,565 |
Sector | Consumer Staples | Health |
52-Week High | $166.68 | $72.61 |
52-Week Low | $112.77 | $43.31 |
Enterprise Value | $31.72B | $11.39B |
Dividend Yield | 3.24% | 0.44% |
Typical Hold Time | — | 64 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Bio-Techne (TECH) trades at $72.50, near its 52-week high of $72.70, with a slight daily decline of 0.08%. Technical indicators show a bullish trend, while valuation ratios like a P/E of 62.5 suggest premium pricing. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share is a key development. Earnings have been mixed, with a beat in Q2 2026 but a miss in Q1 2026, and net income declined to $73.40 million in 2025 from $168 million in 2024.
The stock's outlook is supported by the pending acquisition, offering a near-term upside to the $73.00 buyout price. However, high valuation and earnings volatility pose risks. Analyst sentiment is balanced with 46% buy ratings, but no sell recommendations. Investors should weigh the acquisition premium against fundamental concerns like margin compression.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Constellation Brands, Inc. is a US producer and marketer of beer, wine, and spirits, known for importing Mexican beer brands Corona and Modelo alongside a portfolio of wine and craft spirits labels.
Read more on STZ →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →